22101-Breast Cancer-NA-150

Breast Cancer

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • Details

ClinicalTrials.gov ID: NCT05514054
Diagnosis Type: NA
USOR Number:

  • Address

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

Search by practice name, trial titles, indicators and specific disease types.